Initial Public Offering
Baird served as a co-manager on this offering
AboutOxford Immunotec Global PLC (“Oxford” or the “Company”) (NASDAQ: OXFD) recently completed an initial public offering of 6,164,000 common shares at a price of $12.00 per share, generating gross proceeds of approximately $73.9 million. Oxford intends to use the net proceeds from the offering to hire additional sales, marketing and customer service personnel and expand marketing programs both in the United States and outside the United States. The Company also plans to fund research and development programs dedicated to development of new diagnostic tests in the field of immunology, repay borrowings outstanding under its current credit facility and for working capital and other general corporate purposes.
Oxford is a global, commercial-stage diagnostics company committed to improving patient care by providing tests in the field of immunology. Oxford’s proprietary T-SPOT® technology platform allows the Company to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body’s immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. Oxford is headquartered near Oxford, United Kingdom and in Marlborough, Massachusetts.
For additional information about this transaction, please contact:
- November 2013
- Oxford Immunotec Global PLC
- Target Location